Deflazacort clinical trials
Also written Emflaza®.
How each study uses deflazacort is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 9 Feb 2017 · EMFLAZA · NDA 208684 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
14 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 5
PTC Therapeutics (8) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Yuzuncu Yıl University (1) · University of Rochester (1) · Catabasis Pharmaceuticals (1) · Ludwig-Maximilians - University of Munich (1) · Parc de Salut Mar (1)
Often tested with
Tested in the same studies.
Prednisone (1) · Midazolam (1) · Rifampin (1) · Clarithromycin (1) · 6α-methylprednisone (1) · Dexamethasone (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunosuppressive Agents source
Studies
Open first, then newest update. How each study uses deflazacort is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- Deflazacort Vs. Prednisolone in Acute-stage ABPAActive, not recruitingPhase 2/3Post Graduate Institute of Medical Education and Research, ChandigarhNCT04227483Written as DeflazacortHow we know
- Evaluation of the Effects of Pre-operative Deflazacort on Post-operative Pain, Edema and TrismusActive, not recruitingPhase 4Yuzuncu Yıl UniversityNCT04365088Written as Deflazacort 30 MG Oral TabletHow we know
- Finding the Optimum Regimen for Duchenne Muscular DystrophyCompletedPhase 3University of RochesterNCT01603407Written as DeflazacortHow we know
- A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)TerminatedPhase 3PTC TherapeuticsNCT03783923Written as DeflazacortHow we know
- Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping ControlsStatus unknownPhase 1Parc de Salut MarNCT04791345Written as DeflazacortHow we know
- Study of Edasalonexent With Midazolam and Deflazacort in Healthy SubjectsCompletedPhase 1Catabasis PharmaceuticalsNCT04543370Written as Deflazacort 36Mg TabHow we know
- A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)WithdrawnPhase 3PTC TherapeuticsNCT03642145Written as DeflazacortHow we know
- An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability DeflazacortCompletedPhase 1PTC TherapeuticsNCT02295748Written as DeflazacortHow we know
- Food Effect and Bioavailability of Deflazacort Formulations in Healthy VolunteersCompletedPhase 1PTC TherapeuticsNCT02485431Written as DeflazacortHow we know
- Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of DeflazacortCompletedPhase 1PTC TherapeuticsNCT02286635Written as Deflazacort and rifampinHow we know
- A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort PharmacokineticsCompletedPhase 1PTC TherapeuticsNCT02286622Written as DeflazacortHow we know
- A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular DystrophyCompletedPhase 1PTC TherapeuticsNCT02251600Written as DeflazacortHow we know
- A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort PharmacokineticsCompletedPhase 1PTC TherapeuticsNCT02286609Written as DeflazacortHow we know
- Deflazacort in DysferlinopathiesCompletedPhase 2/3Ludwig-Maximilians - University of MunichNCT00527228Written as deflazacortHow we know
Given beside what is tested · 1 — deflazacort is usual care or a partner of the new treatment
Codes
What other systems call deflazacort · ClinicalTrials.gg INT002752
- MeSH (NLM) C021988deflazacortConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KR5YZ6AE4BDEFLAZACORTConfirmed FDA, NLM, Wikidata
- RxNorm 22396Confirmed FDA, Wikidata
- Wikidata Q779118deflazacortConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C87230DeflazacortOne source FDA
- DrugBank DB11921One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C021988 | deflazacort | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KR5YZ6AE4B | DEFLAZACORT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 22396 | — | Confirmed FDA, Wikidata |
| Wikidata | Q779118 | deflazacort | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C87230 | Deflazacort | One source FDA |
| DrugBank | DB11921 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.